However, 17% of ovarian cancer patients in the TCGA database also have homozygous deletions or significantly downregulated RB1; these patients are less likely to receive significant benefit from CDK4/6 inhibitor therapy. This evidence concerns the gene CDK4 and ovarian carcinoma.